Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Open Treatment Clear all
Completed Phase 2 Interventional Results available

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

NCT00110617
View directory record Official record
Conditions
Sickle Cell Disease, Iron Overload, Hemolytic Anemia
Interventions
Deferasirox (ICL670), Deferoxamine (DFO)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Mobile, Alabama • Loma Linda, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Sep 17, 2026, 5:35 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

NCT06171750
View directory record Official record
Conditions
Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
Interventions
tolododekin alfa, Cemiplimab
Drug
Lead sponsor
Ankyra Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Phase 4 Interventional Results available

Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

NCT00527618
View directory record Official record
Conditions
Genital Herpes, HIV Infection
Interventions
valacyclovir, acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Sep 17, 2026, 5:35 AM EDT
Withdrawn Phase 1 Interventional

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

NCT05238324
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
Genetic HMI-203
Biological
Lead sponsor
Homology Medicines, Inc
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
5
States / cities
Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 17, 2026, 5:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

NCT05222555
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Tafasitamab, Lenalidomide
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Morristown, New Jersey • Dallas, Texas • Olympia, Washington
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Not applicable Interventional Results available

iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology

NCT02731326
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
AliveCor, Behavioral Altering Messaging
Device · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 17, 2026, 5:35 AM EDT
Terminated Not applicable Interventional Results available

Timing of PDA Closure and Respiratory Outcome in Premature Infants

NCT00802685
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
Early ibuprofen, Late ibuprofen expectant group (placebo)
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
1 Day to 14 Days
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Sep 17, 2026, 5:35 AM EDT
Active, not recruiting Not applicable Interventional

An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms

NCT05805176
View directory record Official record
Conditions
ADHD
Interventions
ADHD Therapy
Device
Lead sponsor
Lumos Labs, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Jacksonville, Florida • Lakeland, Florida • Rochester Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

NCT01726517
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 17, 2026, 5:35 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT02245568
View directory record Official record
Conditions
Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia
Interventions
LMTM
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Not listed
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Phoenix, Arizona • Fountain Valley, California • Laguna Hills, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Phase 3 Interventional Results available

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

NCT01332968
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Bendamustine, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
12
States / cities
Springdale, Arkansas • Irvine, California • Post Falls, Idaho + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

NCT02057718
View directory record Official record
Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions
LUM001 (Maralixibat)
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Months to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

NCT01613118
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
RE-021 (Sparsentan), Irbesartan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
8 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
28
States / cities
San Diego, California • Torrance, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Not applicable Interventional Results available

Development of a Multifunctional Rehabilitation Device for Persons With Parkinson's Disease

NCT05586490
View directory record Official record
Conditions
Parkinson Disease
Interventions
Multifunctional RehabilitationDevice (MRD), existing standard rehabilitation device
Device
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 17, 2026, 5:35 AM EDT
Approved For Marketing No phase listed Expanded access

Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects

NCT00918424
View directory record Official record
Conditions
Epilepsy
Interventions
Oxcarbazepine Extended Release
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
6
States / cities
Loxahatchee Groves, Florida • Palm Beach, Florida • Rockville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Phase 3 Interventional Results available

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

NCT00528567
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Standard adjuvant chemotherapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
44
States / cities
Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Non-rebreather at Flush Rate Compared to Bag Valve Mask With Assist

NCT02841592
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
Flush rate oxygen, Flush rate oxygen with assist
Other
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03430011
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JCARH125, JCARH125 + anakinra
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 17, 2026, 5:35 AM EDT
Terminated Phase 3 Interventional Results available

HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis

NCT01882764
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
HMPL-004, Placebo
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Agawam, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

NCT02804399
View directory record Official record
Conditions
Healthy
Interventions
PF-06463922, rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 17, 2026, 5:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

NCT03555149
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Regorafenib, Atezolizumab, Imprime PGG, Bevacizumab, Isatuximab, Selicrelumab, Idasanutlin, AB928, LOAd703
Drug · Genetic
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 17, 2026, 5:35 AM EDT
Not yet recruiting Not applicable Interventional

OCM™ Treatment With Routine Care in Venous Leg Ulcers Compared to Routine Care Treatment Alone.

NCT07754526
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
Omeza OCM™ Wound Matrix, Routine Care
Device · Procedure
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 17, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants

NCT05062785
View directory record Official record
Conditions
Out-Of-Hospital Cardiac Arrest, Healthy
Interventions
Intranasal insulin
Drug
Lead sponsor
Robert Silbergleit
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 17, 2026, 5:35 AM EDT
Not listed Phase 4 Interventional

Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia

NCT03422640
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Apremilast
Drug
Lead sponsor
Bellevue Dermatology
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Sep 17, 2026, 5:35 AM EDT